Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07089199). This is a study registration, not published results. Lead sponsor: Qilu Hospital of Shandong University. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 34 participants (ESTIMATED). Conditions: NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxel. Interventions: DRUG: neoadjuvant therapy; PROCEDURE: Surgery; DRUG: Adjuvant therapy. Primary outcome measures: pathological complete response (pCR) , Up to approximately 8 weeks following completion of neoadjuvant treatment. Brief summary: This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage II-III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.